BRCA1 and breast cancer: Patients with advanced or recurrent metastatic BC with somatic mutations in the BRCA1/2 genes are more sensitive to DNA-damaging drugs, such as platinum drugs, or poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib, due to homologous repair deficiency [10].